KLBF Share Price Performance
Rp1,415.00
-230.00 (-13.98%)
Price Rp1,415.00
Share PriceRp1,415.00
KLBF Community Narratives
There are no narratives available yet.
Recent KLBF News & Updates
No updates
PT Kalbe Farma Tbk. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 73.71
- Gross Margin
- 39.46%
- Net Profit Margin
- 10.15%
- Debt/Equity Ratio
- 1.9%
PT Kalbe Farma Tbk. Competitors
About KLBF
- Founded
- 1966
- Employees
- 12841
- CEO
- WebsiteView website
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic divisions. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. The company was incorporated in 1966 and is based in Jakarta, Indonesia.
Indonesian Market Performance
- 7 Days: -2.0%
- 3 Months: 9.5%
- 1 Year: 7.9%
- Year to Date: 6.1%
Over the last 7 days, the market has dropped 2.0%, driven by a pullback of 3.8% in the Financials sector. In contrast, the Communication Services sector has actually gained 4.1%. In contrast to the last week, the market is actually up 7.9% over the past year. As for the next few years, earnings are expected to grow by 7.4% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading